JPS6352014B2 - - Google Patents
Info
- Publication number
- JPS6352014B2 JPS6352014B2 JP2130379A JP2130379A JPS6352014B2 JP S6352014 B2 JPS6352014 B2 JP S6352014B2 JP 2130379 A JP2130379 A JP 2130379A JP 2130379 A JP2130379 A JP 2130379A JP S6352014 B2 JPS6352014 B2 JP S6352014B2
- Authority
- JP
- Japan
- Prior art keywords
- mecobalamin
- effect
- mouse
- cells
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005321 mecobalamin Drugs 0.000 claims description 29
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims description 29
- 235000007672 methylcobalamin Nutrition 0.000 claims description 29
- 239000011585 methylcobalamin Substances 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 14
- 230000036737 immune function Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 230000002584 immunomodulator Effects 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960003290 cortisone acetate Drugs 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108700031361 Brachyury Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- JBJSVEVEEGOEBZ-SCZZXKLOSA-K coenzyme B(3-) Chemical compound [O-]P(=O)([O-])O[C@H](C)[C@@H](C([O-])=O)NC(=O)CCCCCCS JBJSVEVEEGOEBZ-SCZZXKLOSA-K 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000008216 juvenile development Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2130379A JPS55113721A (en) | 1979-02-27 | 1979-02-27 | Immunity regulator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2130379A JPS55113721A (en) | 1979-02-27 | 1979-02-27 | Immunity regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55113721A JPS55113721A (en) | 1980-09-02 |
| JPS6352014B2 true JPS6352014B2 (enrdf_load_stackoverflow) | 1988-10-17 |
Family
ID=12051371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2130379A Granted JPS55113721A (en) | 1979-02-27 | 1979-02-27 | Immunity regulator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55113721A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02131115U (enrdf_load_stackoverflow) * | 1989-03-31 | 1990-10-31 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787527B1 (en) * | 1994-11-10 | 2004-09-07 | Duke University | Methods of preventing and treating HIV infection |
| WO2000038696A1 (en) * | 1998-12-28 | 2000-07-06 | Allergy Limited, Llc | Cyanocobalamin (vitamin b12) treatment in allergic disease |
| KR100732100B1 (ko) * | 2003-05-07 | 2007-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 메틸코발라민 함유 동결 건조 제제 및 그의 제조 방법 |
| DE102010023626A1 (de) * | 2010-06-14 | 2011-12-15 | Thomas Schütz | Verwendung von Corrinoiden zur arzneilichen Anwendung bei Fell- und Hauterkrankungen bei Klein- und Groß-Tieren (warm- und kaltblütig), (z.B. bei Fischen, Vögeln, Pferden, Rindern, Kamelen, Hunden, Katzen, Reptilien) |
-
1979
- 1979-02-27 JP JP2130379A patent/JPS55113721A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02131115U (enrdf_load_stackoverflow) * | 1989-03-31 | 1990-10-31 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55113721A (en) | 1980-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU682818B2 (en) | Use of substituted adenine derivatives for treating multiple sclerosis | |
| JPH02108636A (ja) | 抗腫瘍性組合せ製剤 | |
| JPS60224697A (ja) | チゴゲニンセロビオシドおよび医薬 | |
| KR19990087113A (ko) | 약품으로 인한 독성을 경감할 수 있는 산화질소 도너 | |
| EP0797448B1 (en) | Combination preparation, containing cyclosporin a or fk506 or rapamycin and a xanthine derivative | |
| EP1383515A1 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
| EP0253962B1 (en) | Use of adenosine derivatives as anti-dementia agents | |
| EP0620004A1 (en) | Medicinal composition | |
| EP0344880A2 (en) | Pharmaceutical compositions with anti-cancer activity | |
| CN113493415B (zh) | 一种青藤碱衍生物代谢产物及其制备方法、药物组合物和用途 | |
| KR101189693B1 (ko) | 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포 림프종의 치료 | |
| JPH0134970B2 (enrdf_load_stackoverflow) | ||
| AU628113B2 (en) | 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition | |
| JPS6352014B2 (enrdf_load_stackoverflow) | ||
| US20050085464A1 (en) | Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human | |
| US3934036A (en) | N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent | |
| US5733915A (en) | Use of azathioprine to treat crohn's disease | |
| US5994328A (en) | Hypoestoxides, derivatives and agonists thereof for use as anticancer agents | |
| EP0650726A1 (en) | 4-Piperidino-piperidine for the treatment of tumor | |
| AU734807B2 (en) | Dhea combination therapy | |
| EP0476391B1 (en) | Anti-AIDS virus composition containing cepharanthine as active compound | |
| US3852433A (en) | Uridine-5-monophosphate compositions | |
| WO2002011736A1 (en) | Naadp analogues for modulating t-cell activity | |
| CA2191230C (en) | 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease | |
| KR950007909B1 (ko) | 치매 치료제 |